UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 69

Sortiert nach

Effects of the α4β2 Partial Agonist Varenicline on Brain Activity and Working Memory in Abstinent Smokers

Biological psychiatry (1969), 2010-04, Vol.67 (8), p.715-721

2010

Volltextzugriff (PDF)

Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers

Proceedings of the National Academy of Sciences - PNAS, 2011-05, Vol.108 (22), p.9268-9273

2011

Volltextzugriff (PDF)

Author Correction: Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD

NPJ primary care respiratory medicine, 2021-12, Vol.31 (1), p.49-49, Article 49

2021

Volltextzugriff (PDF)

Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA

Respiratory medicine, 2018-06, Vol.139, p.65-71

2018

Volltextzugriff (PDF)

Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study

BMC pulmonary medicine, 2021-07, Vol.21 (1), p.253-10, Article 253

2021

Volltextzugriff (PDF)

A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control

Human vaccines & immunotherapeutics, 2017-07, Vol.13 (7), p.1640-1652

2017

Volltextzugriff (PDF)

Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD

NPJ primary care respiratory medicine, 2018-08, Vol.28 (1), p.32-9, Article 32

2018

Volltextzugriff (PDF)

Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study

Pulmonary therapy, 2019-12, Vol.5 (2), p.191-200

2019

Volltextzugriff (PDF)

Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study

Pulmonary therapy, 2019-06, Vol.5 (1), p.69-80

2019

Volltextzugriff (PDF)

The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models

Multidisciplinary respiratory medicine, 2018-10, Vol.13 (1), p.38-38, Article 38

2018

Volltextzugriff (PDF)

Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study

Pulmonary therapy, 2019-12, Vol.5 (2), p.179-190

2019

Volltextzugriff (PDF)

Nicotine abstinence-induced cerebral blood flow changes by genotype

Neuroscience letters, 2008-06, Vol.438 (3), p.275-280

2008

Volltextzugriff (PDF)

Clinical Features of Influenza and Acute Respiratory Illness in Older Adults at Least 50 Years of Age in an Outpatient Setting in the Republic of Korea: a Prospective, Observational, Cohort Study

Journal of Korean Medical Science, 2017, 32(3), 225, pp.407-414

2017

Volltextzugriff (PDF)

Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment

The pharmacogenomics journal, 2008-12, Vol.8 (6), p.391-399

2008

Volltextzugriff (PDF)

DESCRIPTION OF EXACERBATION HISTORY PRIOR TO INITIAL MAINTENANCE THERAPY AMONG PATIENTS WITH COPD IN THE UNITED STATES

Chest, 2019-10, Vol.156 (4), p.A452-A453

2019

Volltextzugriff (PDF)

Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial

Nicotine & tobacco research, 2007-11, Vol.9 (11), p.1237-1241

2007

Volltextzugriff (PDF)

UMECLIDINIUM/VILANTEROL (UMEC/VI) COMPARED WITH TIOTROPIUM (TIO) FOR TIME-TO-FIRST INPATIENT ADMISSION AMONG PATIENTS WITH COPD IN A MANAGED CARE POPULATION

Chest, 2020-10, Vol.158 (4), p.A1716-A1717

2020

Volltextzugriff (PDF)

IMPACT OF UMECLIDINIUM/VILANTEROL (UMEC/VI) VS TIOTROPIUM (TIO), FLUTICASONE PROPIONATE/SALMETEROL (FP/SAL), AND BUDESONIDE/FORMOTEROL (B/F) ON TIME-TO-FIRST SEVERE EXACERBATION AMONG PATIENTS WITH COPD WITH HIGH COMORBIDITIES AND HIGH COSTS

Chest, 2020-10, Vol.158 (4), p.A1718-A1719

2020

Volltextzugriff (PDF)

MEDICATION ADHERENCE AND COPD-RELATED COSTS AMONG PATIENTS WITH COPD TREATED WITH UMECLIDINIUM/VILANTEROL (UMEC/VI) VS TIOTROPIUM (TIO)

Chest, 2020-10, Vol.158 (4), p.A1720-A1721

2020

Volltextzugriff (PDF)

Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials

Pulmonary pharmacology & therapeutics, 2019-08, Vol.57, p.101802-101802, Article 101802

2019

Volltextzugriff (PDF)

ECONOMIC IMPACT OF EARLY USE OF UMEC/VI COMPARED WITH LATER USE IN PATIENTS WITH COPD

Chest, 2018-10, Vol.154 (4), p.767A-768A

2018

Volltextzugriff (PDF)

Nicotine Dependence Pharmacogenetics: Role of Genetic Variation in Nicotine-Metabolizing Enzymes

Journal of neurogenetics, 2009, Vol.23 (3), p.252-261

2009

Volltextzugriff (PDF)

COMPARISON BETWEEN UMEC/VI AND FF/VI BASED ON BASELINE FEV1 REVERSIBILITY: SUB-ANALYSIS FROM THE IMPACT TRIAL

Chest, 2019-10, Vol.156 (4), p.A470-A473

2019

Volltextzugriff (PDF)

COMPARISON BETWEEN FF/UMEC/VI VS UMEC/VI AND FF/VI AND UMEC/VI VS FF/VI BASED ON BASELINE EXACERBATION HISTORY AND FEV1: SUB-ANALYSIS FROM THE IMPACT TRIAL

Chest, 2019-10, Vol.156 (4), p.A475-A478

2019

Volltextzugriff (PDF)

Nicotine dependence: biology, behavior, and treatment

Annual review of medicine, 2009-01, Vol.60 (1), p.247-260

2009

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(65)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(44)
Life Sciences & Biomedicine
(41)
Humans
(38)
Female
(21)
Male
(21)
Adult
(19)
Middle Aged
(18)
Nicotine
(15)
Chronic Obstructive Pulmonary Disease
(13)
Respiratory System
(13)
Biological And Medical Sciences
(12)
Copd
(11)
Patients
(11)
Aged
(10)
Medical Sciences
(10)
Addiction
(9)
Genotype
(9)
Pulmonary Disease, Chronic Obstructive - Drug Therapy
(9)
Tobacco Use Disorder - Genetics
(9)
Medical Research
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Effects of the α4β2 Partial Agonist Varenicline on Brain Activity and Working Memory in Abstinent Smokers

Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers

Author Correction: Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD

Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA

Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study

A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control

Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD

Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study

Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study

The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models

Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study

Nicotine abstinence-induced cerebral blood flow changes by genotype

Clinical Features of Influenza and Acute Respiratory Illness in Older Adults at Least 50 Years of Age in an Outpatient Setting in the Republic of Korea: a Prospective, Observational, Cohort Study

Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment

DESCRIPTION OF EXACERBATION HISTORY PRIOR TO INITIAL MAINTENANCE THERAPY AMONG PATIENTS WITH COPD IN THE UNITED STATES

Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial

UMECLIDINIUM/VILANTEROL (UMEC/VI) COMPARED WITH TIOTROPIUM (TIO) FOR TIME-TO-FIRST INPATIENT ADMISSION AMONG PATIENTS WITH COPD IN A MANAGED CARE POPULATION

IMPACT OF UMECLIDINIUM/VILANTEROL (UMEC/VI) VS TIOTROPIUM (TIO), FLUTICASONE PROPIONATE/SALMETEROL (FP/SAL), AND BUDESONIDE/FORMOTEROL (B/F) ON TIME-TO-FIRST SEVERE EXACERBATION AMONG PATIENTS WITH COPD WITH HIGH COMORBIDITIES AND HIGH COSTS

MEDICATION ADHERENCE AND COPD-RELATED COSTS AMONG PATIENTS WITH COPD TREATED WITH UMECLIDINIUM/VILANTEROL (UMEC/VI) VS TIOTROPIUM (TIO)

Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials

ECONOMIC IMPACT OF EARLY USE OF UMEC/VI COMPARED WITH LATER USE IN PATIENTS WITH COPD

Nicotine Dependence Pharmacogenetics: Role of Genetic Variation in Nicotine-Metabolizing Enzymes

COMPARISON BETWEEN UMEC/VI AND FF/VI BASED ON BASELINE FEV1 REVERSIBILITY: SUB-ANALYSIS FROM THE IMPACT TRIAL

COMPARISON BETWEEN FF/UMEC/VI VS UMEC/VI AND FF/VI AND UMEC/VI VS FF/VI BASED ON BASELINE EXACERBATION HISTORY AND FEV1: SUB-ANALYSIS FROM THE IMPACT TRIAL

Nicotine dependence: biology, behavior, and treatment

Suchergebnisse filtern